Cogent Biosciences Inc. (NASDAQ: COGT) presented preclinical data for its JAK2 V617F inhibitor CGT1145 at the European Hematology Association Congress ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE